SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was ...

Primarily because most people like a good underdog story, and also because Nintendo has built a reputation for being very, ...

Enlivex Therapeutics Ltd. (ENLV) is making significant progress in immunotherapy with its innovative Allocetra™ technology.

In September of last year, and in light of a corresponding Japanese patent infringement suit, I published an article ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

The Philippines and Japan have partnered to intensify the country’s efforts to combat counterfeit goods, especially in identifying fake Japanese products in the local market. In a statement Monday, ...

In this edition of The Precedent, we outline the decision in Apple Inc. v. Gesture Tech. Partners, LLC. In Apple Inc., v. Gesture Tech Partners, ...

The Japanese Patent Office (JPO) recently granted Envoy Medical Corporation three new patents. On December 2, 2024, the JPO granted Envoy JP Pat. No. 7597846, which relates to providing a patient ...

STATEN ISLAND, N.Y. - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a clinical-stage biopharmaceutical company with a market capitalization of $12.5 million engaged in developing new antibiotics, has ...

To date, Acurx has obtained three U.S. patents, one Israeli patent and now one Japanese patent, in each case, which cover the ACX-375C program, relating to DNA Polymerase IIIC Inhibitors ...